Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
9 Results for "
muscle atrophy pathways
" in MedChemExpress (MCE) Product Catalog:
Products (9)
9 Results for "muscle atrophy pathways" in MCE Product Catalog:
7
7 Publications Verification
Cat. No.: HY-18102
CAS No.: 1215085-92-9
Target:
Research Areas:
GLPG0492 is an orally active, non-steroidal selective androgen receptor modulator. GLPG0492 exerts functional transactivation by binding to the ligand-binding domain of the receptor, exhibiting preferential partial agonist activity in muscle and bone tissues with low activity in reproductive tissues. GLPG0492 effectively counteracts muscle atrophy-related pathways, significantly enhances muscle strength, maintains motor ability, reduces fibrosis and improves electrophysiological parameters. GLPG0492 prevents immobilization-induced muscle atrophy and regulates muscle mass homeostasis, serving as a valuable tool compound for studies on Duchenne muscular dystrophy, muscle loss and various types of disuse musculoskeletal atrophy .
2
Category:
Other Monoterpenes other families Terpenoids Other Diseases Plants Disease Research Fields
Target:
1
1 Cited Publications
Cat. No.: HY-N2787
CAS No.: 53846-50-7
Cat. No.: HY-N3225
CAS No.: 33606-81-4
Category:
Cat. No.: HY-P99818
CAS No.: 1169766-01-1
Synonyms: ACE-031
Target:
Research Areas:
Cat. No.: HY-18102BS
Cat. No.: HY-183504
CAS No.: 3039974-35-8
Target:
Research Areas:
ActRIIB-IN-3 is a ActRIIB inhibitor. ActRIIB-IN-3 inhibits the ActRIIB protein in the MSTN pathway and induces the reversal of skeletal muscle atrophy associated with cancer cachexia. ActRIIB-IN-3 is applicable for the research of cancer cachexia .
Cat. No.: HY-183005
CAS No.: 3039974-31-4
Target:
Research Areas:
ActRIIB-IN-1, 7-azaindole compound is an orally active activin type II receptor B (ActRIIB) inhibitor with an IC50 of 1.8 nM. ActRIIB-IN-1 can alleviate weight loss, muscle atrophy and decreased muscle strength caused by tumor cachexia, as well as improve appetite. ActRIIB-IN-1 can be used for the research of cancer cachexia .
Cat. No.: HY-186252
CAS No.: 3103571-04-3
Research Areas:
Neurological Disease Metabolic Disease Inflammation/Immunology Endocrinology
GPR133 agonist 1 is an orally active GPR133/ADGRD1 agonist with an EC50 of 1.6 nM (293T cells). GPR133 agonist 1 activates GPR133, thereby regulating the downstream cAMP signaling pathway. GPR133 agonist 1 enhances muscle strength and endurance in mice. GPR133 agonist 1 can be used in research related to muscular atrophy, myasthenia, sarcopenia, erectile dysfunction, vestibular dysfunction, obesity, and non-alcoholic fatty liver disease .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
